109 related articles for article (PubMed ID: 3717188)
1. In vitro models in the study of antibiotic therapy of infections in neutropenic patients.
Zinner SH; Blaser J
Am J Med; 1986 May; 80(5C):40-4. PubMed ID: 3717188
[TBL] [Abstract][Full Text] [Related]
2. Immunocompromised animal models for the study of antibiotic combinations.
Calandra T; Glauser MP
Am J Med; 1986 May; 80(5C):45-52. PubMed ID: 3087166
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic use in neonatal sepsis.
Yurdakök M
Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468
[TBL] [Abstract][Full Text] [Related]
4. Laboratory support for choosing and monitoring antimicrobial therapy in severely ill patients.
Zinner SH; Blaser J; Gaya H
Am J Med; 1986 May; 80(5C):59-63. PubMed ID: 3717189
[TBL] [Abstract][Full Text] [Related]
5. In vitro models for the study of combination antibiotic therapy in neutropenic patients.
Zinner SH; Dudley M; Blaser J
Am J Med; 1986 Jun; 80(6B):156-60. PubMed ID: 3728526
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of single-agent therapy with azlocillin, ticarcillin, and amikacin and beta-lactam/amikacin combinations for treatment of Pseudomonas aeruginosa bacteremia in granulocytopenic rats.
Johnson DE; Thompson B
Am J Med; 1986 May; 80(5C):53-8. PubMed ID: 3636060
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
[TBL] [Abstract][Full Text] [Related]
8. The use of aminoglycosides in neutropenic patients.
Cometta A; Glauser MP
Schweiz Med Wochenschr Suppl; 1996; 76():21S-27S. PubMed ID: 8677415
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa.
Aoki N; Tateda K; Kikuchi Y; Kimura S; Miyazaki C; Ishii Y; Tanabe Y; Gejyo F; Yamaguchi K
J Antimicrob Chemother; 2009 Mar; 63(3):534-42. PubMed ID: 19147523
[TBL] [Abstract][Full Text] [Related]
10. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.
Schentag JJ; Birmingham MC; Paladino JA; Carr JR; Hyatt JM; Forrest A; Zimmer GS; Adelman MH; Cumbo TJ
Semin Respir Infect; 1997 Dec; 12(4):278-93. PubMed ID: 9436955
[TBL] [Abstract][Full Text] [Related]
11. In vitro considerations in monotherapy and combination therapy for severe infections.
Gaya H
Am J Med; 1986 May; 80(5C):75-8. PubMed ID: 3717192
[TBL] [Abstract][Full Text] [Related]
12. [In vitro model for the study of the concentration kinetics of antibiotic combinations and their antibacterial activity].
Patsch R; Koester G; Sandow D; Bretschneider M
Zentralbl Bakteriol Mikrobiol Hyg A; 1986 Nov; 262(4):512-21. PubMed ID: 3541460
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis of bacterial infections with oral antibiotics in neutropenic patients. Lessons from the last two EORTC trials and prospects for the future.
Zinner SH
Schweiz Med Wochenschr Suppl; 1983; 14():7-14. PubMed ID: 6361995
[TBL] [Abstract][Full Text] [Related]
14. Single versus combination antibiotic therapy for pneumonia due to Pseudomonas aeruginosa in neutropenic guinea pigs.
Rusnak MG; Drake TA; Hackbarth CJ; Sande MA
J Infect Dis; 1984 Jun; 149(6):980-5. PubMed ID: 6429255
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of MSI-78 alone and in combination with antibiotics against bacteria responsible for bloodstream infections in neutropenic patients.
Giacometti A; Cirioni O; Kamysz W; D'Amato G; Silvestri C; Licci A; Nadolski P; Riva A; Lukasiak J; Scalise G
Int J Antimicrob Agents; 2005 Sep; 26(3):235-40. PubMed ID: 16122911
[TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of newer beta-lactam antibiotics against gram negative bacilli isolated from neutropenic patients.
Ebenezer S; Lalitha MK; Jesudason MV; Chandy M
Indian J Cancer; 1994 Mar; 31(1):23-6. PubMed ID: 8063332
[TBL] [Abstract][Full Text] [Related]
17. Viridans streptococci in endocarditis and neutropenic sepsis: biofilm formation and effects of antibiotics.
Presterl E; Grisold AJ; Reichmann S; Hirschl AM; Georgopoulos A; Graninger W
J Antimicrob Chemother; 2005 Jan; 55(1):45-50. PubMed ID: 15563519
[TBL] [Abstract][Full Text] [Related]
18. [C-reactive protein concentrations during initial (empiric) treatment of neonatal sepsis].
Janković B; Pasić S; Marković M; Veljković D; Milicić M
Srp Arh Celok Lek; 2001; 129 Suppl 1():17-22. PubMed ID: 15637985
[TBL] [Abstract][Full Text] [Related]
19. Use of breakpoint combination sensitivity testing as a simple and convenient method to evaluate the combined effects of ceftazidime and tobramycin on Pseudomonas aeruginosa and Burkholderia cepacia complex isolates in vitro.
Tunney MM; Scott EM
J Microbiol Methods; 2004 Apr; 57(1):107-14. PubMed ID: 15003693
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic combinations for the empiric treatment of the febrile neutropenic patient.
Walsh TJ; Schimpff SC
Schweiz Med Wochenschr Suppl; 1983; 14():58-63. PubMed ID: 6361993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
